Targeting the epidermal growth factor receptor in solid tumors: Focus on safety

Expert Opinion on Drug Safety

Volumn 13, Issue 5, 2014, Pages 535-549

  Lucchini, Eleonora ^a   Pilotto, Sara ^a   Spada, Elisa ^a   Melisi, Davide ^a   Bria, Emilio ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Adverse events; EGFR; Management strategies; Monoclonal antibodies; Skin rash; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; PANITUMUMAB; SORAFENIB; SUNITINIB; VANDETANIB; ANTINEOPLASTIC AGENT;

ALLERGIC REACTION; CANCER CHEMOTHERAPY; DIARRHEA; DRUG SAFETY; DRUG TARGETING; ELECTROLYTE DISTURBANCE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INTERSTITIAL LUNG DISEASE; MUCOSA INFLAMMATION; NAUSEA; PARONYCHIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; QT PROLONGATION; QUALITY OF LIFE; RASH; REVIEW; SKIN TOXICITY; SOLID TUMOR; VOMITING; XEROSIS; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG ERUPTIONS; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84899090908     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.904283     Document Type: Review

References (76)

1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-99
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358(11):1160-74
3. Amado RG, Wolf M, Peeters M, et al. Wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626-34
4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-71
5. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329- 38
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43
8. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27(33):5538-46
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
11. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8
12. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
14. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007;25(15):1960-6
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
16. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
17. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239-46
18. Sequist LV, Yang JC, Yamamoto N, et al. Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27):3327-34
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
20. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
21. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
22. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase iii trial. J Clin Oncol 2012;30(2):134-41
23. Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011;11(9):1223-31
24. Liang J, E M, Wu G, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase ii clinical trial. Onco Targets Ther 2013;6:1589-96
25. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14(10):953-61
26. Lacouture ME, Anadkat MJ, Bensadoun RJ, Group MSTS. Clinical practice guidelines for the prevention and treatment of egfr inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19(8):1079-95
27. Baas JM, Krens LL, Guchelaar HJ, et al. Recommendations on management of egfr inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev 2012;38(5):505-14
28. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase ii, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(8):1351-7
29. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55(4):657-70
30. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803-12
31. Pinto C, Barone CA, Girolomoni G, American Society of Clinical Oncology; European Society of Medical Oncology. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011;16(2):228-38
32. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334(13):835-40
33. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43(5):845-51
34. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56(2):317-26
35. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic nonsmall cell lung cancer. J Am Acad Dermatol 2013;69(3):463-72
36. Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115(6):1286-99
37. Nardone B, Hensley JR, Kulik L, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 2012;11(11):e61-5
38. Oh WK, McDermott D, Porta C, et al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol 2014;44(1):5-16
39. Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013;13(6):729-36
40. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17(Suppl 1):S18-30
41. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011;18(3):126-38
42. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase iii trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-19
43. Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (vectibix). Oncologist 2007;12(5):577-83
44. Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses her-2. Oncologist 2008;13(10):1114-19
45. Curigliano G, Cardinale D, Suter T, Group EGW. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23(Suppl 7):vii155-66
46. Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf 2013;12(5):687-96
47. Steingart RM, Bakris GL, Chen HX, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 2012;163(2):156-63
48. Hood JD, Meininger CJ, Ziche M, Granger HJ. Vegf upregulates ecnos message, protein, and no production in human endothelial cells. Am J Physiol 1998;274(3 Pt 2):H1054-8
49. van der Veldt AA, de Boer MP, Boven E, et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 2010;21(4):439-46
50. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144(1):3-15
51. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011-19
52. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36(5):295-316
53. Chaudhary P, Gajra A. Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies. Cardiovasc Hematol Agents Med Chem 2010;8(3):156-63
54. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23(7):1672-9
55. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8(4):303-6
56. Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007;7:150
57. Shablak A, Conn A. A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment. Target Oncol 2013. [Epub ahead of print]
58. Jonker DJ, OCallaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8
59. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22(7):1201-8
60. Costa MN, Radhakrishnan K, Edwards JS. Monte carlo simulations of plasma membrane corral-induced EGFR clustering. J Biotechnol 2011;151(3):261-70
61. Vickers MM, Karapetis CS, Tu D, et al. Association of hypomagnesemia with inferior survival in a phase iii, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol 2013;24(4):953-60
62. Jackman DM, Yeap BY, Lindeman NI, et al. Phase ii clinical trial of chemotherapy-naive patients or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25(7):760-6
63. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non - small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47
64. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest oncology group study s0126. J Clin Oncol 2006;24(12):1807-13
65. Burtness B, Goldwasser MA, Flood W, Eastern Cooperative Oncology Group. Phase iii randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 2005;23(34):8646-54
66. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
67. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase ii and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24(30):4914-21
68. Van Cutsem E Peeters M, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
69. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3) 374-9.
70. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase iii trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27(13):2231-7
71. Vaccaro V, Bria E, Sperduti I, et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013;19(28):4511-19
72. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-egfr tyrosine kinase inhibitors: a literature-based metaanalysis of 24 trials. Lung Cancer 2012;78(1):8-15
73. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
74. George S, Reichardt P, Lechner T, et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2012;23(12):3180-7
75. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17(11):3841-9
76. Lacouture ME, Basti S, Patel J, Benson A III. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4(5):236-8